Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Home HIIT bike workout targets fatty liver in new trial

NCT ID NCT07177963

Symptom relief Sponsor: Tang Yida Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether an 8-week home-based high-intensity interval training (HIIT) program, done on a stationary bike and supervised remotely, can reduce liver fat and improve other health measures in 54 adults aged 35-65 with metabolic dysfunction-associated fatty liver disease (MAFLD). Participants will do short bursts of intense pedaling followed by easy recovery, with the workout tailored to their fitness level. The goal is to see if this time-efficient exercise is safe, feasible, and effective for managing MAFLD.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
high-intensity interval training (HIIT) on a stationary bike
What this could lead to
If it works, this could offer a time-efficient, home-based exercise option to reduce liver fat and improve metabolic health in people with MAFLD.
What could go wrong
This is a small, early-stage trial with only 54 participants and no control group for comparison. Results may not apply to everyone, and the exercise program may be too intense for some.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 54 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Apr 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Adults age 35\~65 years Nonalcoholic fatty liver diagnosed by abdominal ultrasonography In conjunction with at least one cardiometabolic risk factor: * Overweight or Obesity: ≥ 24kg/m2，or waist circumference ≥ 90 cm in men and \> 85 cm in women, or excessive body fat mass * Prediabetes or type 2 diabetes mellitus: HbA1c ≥ 5.7%, or fasting plasma glucose ≥ 6.1mmol/L, or 2-h plasma glucose during OGTT ≥ 7.8mmol/L * Plasma triglycerides ≥ 1.7 mmol/L (\>-150 mg/dl) or lipid-lowering treatment * HDL-cholesterol ≤ -1.0 mmol/L in men and ≤ -1.3 mmol/L in women or lipid-lowering treatment * Blood pressure ≥ 130/85 mmHg or treatment for hypertension Exclusion Criteria: * Contraindications for Cardiopulmonary Exercise Testing * The electrocardiogram (ECG) results during cardiopulmonary exercise testing (CPET) showed positive findings * Receiving GLP-1 receptor agonists, SGLT-2i, or taking \>2 antihypertensive/hypoglycemic/lipid-lowering/ antiarrhythmic drugs * Taking dietary supplements (e.g., fish oil products, over-the-counter diet pills, meal replacements) * Mental illness * Other liver diseases * Movement disorder related diseases and lower limb motor injury in the past 6 months * Pregnant, lactating or planning to become pregnant in the near future

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolic dysfunction-associated fatty liver disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease Motor Activity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metabolic dysfunction-associated fatty liver disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Ditan Hospital, Capital Medical University

    Beijing, China

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, China

  • Beijing Youan Hospital, Capital Medical University

    Beijing, China

  • Peking University Third Hospital

    Beijing, China

  • The Fifth Medical Center, Chinese PLA General Hospital

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.